STATINS CHANGED MEDICINE. When lovastatin received FDA approval in 1987 as the first commercial HMG-CoA reductase inhibitor, it launched the most successful class of cardiovascular drugs in history. Statins reduce low-density lipoprotein (LDL) cholesterol — the arterial freight that accumulates in vessel walls, forming the plaques that rupture to cause heart attacks and strokes — by 30 to 50 percent in most patients. The global statin market has prevented millions of cardiovascular deaths and currently serves hundreds of millions of patients worldwide. Yet statins, for all their impact, have a fundamental limitation: they cannot reach guideline-recommended LDL targets in all patients, particularly those with familial hypercholesterolaemia — an inherited condition affecting approximately 1 in 250 people globally that causes dangerously elevated LDL levels from birth, driven not by lifestyle but by genetics. A new drug presented at the American Heart Association Scientific Sessions in November 2025 and published in The New England Journal of Medicine in February 2026 may be on the verge of changing this equation.
Enlicitide decanoate, developed by Merck and known outside the US as MSD’s MK-0616, is an investigational once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. The PCSK9 protein plays a central role in cholesterol homeostasis: it binds to LDL receptors on liver cells and marks them for degradation, reducing the liver’s capacity to clear LDL from the bloodstream. By blocking PCSK9, drugs in this class protect LDL receptors, boost the liver’s LDL clearance capacity, and drive substantial reductions in circulating LDL. The PCSK9 mechanism is validated — injectable monoclonal antibodies targeting PCSK9, including evolocumab and alirocumab, have been approved since 2015 and have demonstrated dramatic LDL reduction in multiple large cardiovascular outcomes trials. Enlicitide targets the same pathway but in a fundamentally different format: a macrocyclic peptide small molecule, taken orally once daily.
The CORALreef Programme: Phase 3 Results
Merck’s CORALreef clinical trial programme is the largest cardiovascular lipid-lowering research effort in recent pharmaceutical history, evaluating enlicitide across more than 19,000 participants in multiple parallel and sequential Phase 3 trials. The pivotal data presented at AHA 2025 came from three completed Phase 3 studies. The CORALreef Lipids study — a randomised, double-blind, placebo-controlled trial of 2,909 participants with atherosclerosis or elevated cardiovascular risk, most already taking statins — demonstrated a 59.7 percent reduction in LDL cholesterol compared to placebo at 24 weeks (p<0.001). The CORALreef HeFH study, focused specifically on patients with heterozygous familial hypercholesterolaemia, showed a 59.4 percent LDL reduction at 24 weeks with a comparable safety and tolerability profile. The CORALreef AddOn study evaluated enlicitide as an add-on to existing statin therapy. All three trials met all primary and secondary endpoints.
Most participants in these trials were already taking moderate- or high-intensity statins, yet their average LDL remained at 96 milligrams per deciliter at baseline — well above guideline-recommended targets of 70 mg/dL for those with atherosclerosis and 55 mg/dL for those at highest risk. The 59 percent LDL reduction achieved with enlicitide would, on average, bring these patients into guideline-recommended range. Importantly, adverse events were similar between enlicitide and placebo groups, with few treatment discontinuations — a safety profile that compares favourably to the existing injectable PCSK9 inhibitors, which have excellent safety records but which require injections every two to four weeks and are subject to the adherence challenges associated with any injectable chronic therapy.
The Oral Advantage: Why Format Matters
The medical significance of enlicitide’s efficacy is well-established. The strategic significance lies in its oral formulation. Injectable PCSK9 inhibitors, despite their proven efficacy in reducing cardiovascular events, have struggled with adoption. Multiple analyses have shown that real-world adherence to injectable therapies for chronic conditions is substantially lower than adherence achieved in clinical trials, particularly as treatment duration extends. Patient reluctance to self-inject, the logistics of refrigeration and disposal, and the psychological barrier of ongoing injection therapy for a condition that is often asymptomatic (high LDL cholesterol causes no symptoms until a heart attack occurs) combine to limit real-world effectiveness of otherwise excellent drugs.
Enlicitide, administered as a once-daily oral tablet, eliminates all of these barriers. It is taken like a statin — with the same daily routine, the same refill process, the same ease of adherence that has made statins the most prescribed class of drugs in history. If approved, it would be the first oral PCSK9 inhibitor — a genuinely novel drug class that combines the biological potency of antibody-based PCSK9 inhibition with the patient accessibility of oral small-molecule therapy. The FDA has awarded enlicitide a National Priority Voucher, signalling recognition of its potential to address a significant unmet medical need. Merck filed for regulatory approval in early 2026.
Scale of Impact: The Cardiovascular Burden
The potential public health impact of an effective, accessible oral PCSK9 inhibitor is substantial. Heterozygous familial hypercholesterolaemia alone affects approximately 1 in 250 individuals — more than 30 million people globally — and is dramatically underdiagnosed and undertreated. Many patients with HeFH cannot achieve guideline LDL targets on statins alone, even at maximum doses, because their genetic condition impairs the fundamental cellular machinery for LDL clearance. For this population, enlicitide represents a genuinely transformative option. The broader hypercholesterolaemia population — which affects approximately 86 million US adults alone — provides an even larger potential indication.
The ongoing CORALreef Outcomes trial, which has enrolled over 14,500 participants and will evaluate enlicitide’s impact on major adverse cardiovascular events (heart attack, stroke, cardiovascular death), will provide the definitive clinical validation of the drug’s cardiovascular benefit. Results are expected in the 2027 to 2028 timeframe. For India, where cardiovascular disease accounts for approximately 28 percent of all deaths — a higher proportional burden than in most Western nations, partly attributable to the particularly high prevalence of genetic dyslipidaemia risk variants in South Asian populations — an affordable, orally administered PCSK9 inhibitor could represent one of the most impactful additions to the cardiovascular medicine toolkit in a generation.
